The study evaluated the use of continuous-flow left ventricular assist devices (LVADs) in patients awaiting heart transplantation. A total of 133 patients with end-stage heart failure who were on a waiting list for heart transplantation were enrolled and underwent implantation of the HeartMate II LVAD. The primary outcomes were the proportions of patients who, at 180 days, had undergone transplantation, had cardiac recovery, or had ongoing mechanical support while remaining eligible for transplantation. The median duration of support was 126 days, and the survival rate during support was 75% at 6 months and 68% at 12 months. At 3 months, therapy was associated with significant improvement in functional status and quality of life. Major adverse events included postoperative bleeding, stroke, right heart failure, and percutaneous lead infection. The study concluded that a continuous-flow LVAD can provide effective hemodynamic support for at least 6 months in patients awaiting heart transplantation, with improved functional status and quality of life.The study evaluated the use of continuous-flow left ventricular assist devices (LVADs) in patients awaiting heart transplantation. A total of 133 patients with end-stage heart failure who were on a waiting list for heart transplantation were enrolled and underwent implantation of the HeartMate II LVAD. The primary outcomes were the proportions of patients who, at 180 days, had undergone transplantation, had cardiac recovery, or had ongoing mechanical support while remaining eligible for transplantation. The median duration of support was 126 days, and the survival rate during support was 75% at 6 months and 68% at 12 months. At 3 months, therapy was associated with significant improvement in functional status and quality of life. Major adverse events included postoperative bleeding, stroke, right heart failure, and percutaneous lead infection. The study concluded that a continuous-flow LVAD can provide effective hemodynamic support for at least 6 months in patients awaiting heart transplantation, with improved functional status and quality of life.